Patrocinadores de la SETGyC

Oro

BD

BD Biosciences is a world leader in bringing innovative diagnostic and research tools to life science researchers, clinical researchers, laboratory professionals and clinicians who are involved in basic research, drug discovery and development, biopharmaceutical production and disease management. The BD Biosciences segment is focused on continually advancing the science and applications associated with cellular analysis and products that help grow living cells and tissue. Products/Services · Fluorescence-activated cell sorters and analyzers · Monoclonal antibodies and kits for cell analysis · Reagent systems for life science research · Cell imaging systems · Laboratory products for tissue culture and fluid handling · Cell culture media and supplements for biopharmaceutical manufacturing

TERCEL

The Spanish cell therapy network (TerCel) is a collaborative research project organized by the Spanish National Institute of Health Carlos III that started in 2003, to promote research in cell therapy and translate the scientific advances in this field to the clinic. Based on a multidisciplinary approach and the interaction and cooperation between 33 groups of basic and clinical scientists across Spain, the main objective of TerCel is to develop new medical therapies based on the use of stem cells for cardiovascular diseases, neurodegenerative diseases and osteo-articular, immune-hematologic and metabolic diseases. www.red-tercel.com

TiGenix

TiGenix is an advanced biopharmaceutical company developing novel therapies for serious medical conditions by exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells. TiGenix´ lead product, Alofisel (darvadstrocel), previously Cx601, received European Commission (EC) approval for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. A global Phase III trial intended to support a future U.S. Biologic License Application (BLA) started in 2017. TiGenix has recently been acquired by Takeda, a global pharmaceutical company active in gastroenterology.

Rocket

Rocket Pharma is a clinical-stage gene therapy company with a multi-platform approach for the treatment of patients with devastating diseases. We leverage LV and AAV transduction strategies towards first-in-class programs. Hall­marks of Rocket’s vision include: 1) a high threshold for the selection of quality programs, 2) leverage of deep industry know-how through a world-class team and manufacturing partnerships and 3) a laser focus on optimizing and innovating gene therapy product parameters through a seasoned scientific approach that de-risks programs as they enter clinical trials.www.rocketpharma.com

VIVET Therapeutics

Vivet Therapeutics is a gene therapy biotech company with headquarters in Paris, France, dedicated to the research, development and future commercialization of gene therapy products for inherited liver disorders with high medical need.

Recently named as Fierce 15 biotech company, Vivet is committed to make a significant difference for patients facing rare metabolic diseases, with Wilson’s disease being our lead indication. Vivet has a strong presence in Spain through its research subsidiary and its strategic collaboration with Fundación para la Investigación Médica Aplicada (FIMA) at the Centro de Investigación Medica Aplicada (CIMA, University of Navarra, Spain), a leading research organization in the field of Gene Therapy. Vivet also has licensed the use of novel proprietary AAV vector gene therapy technology to treat metabolic diseases and certain patent-protected Anc80 AAV gene therapy vectors from Massachusetts Eye and Ear (MEE), a teaching hospital of Harvard Medical School, Boston. Anc80 is a next-generation gene therapy technology designed to increase gene expression levels in the liver.

Plata

VCN

VCN Biosciences is a privately-owned company focused in the development of new therapeutic approaches for tumors that lack effective treatment. The company uses oncolytic adenovirus technology platform to design highly selective and efficient agents that replicate and self-amplify exclusively in tumor cells. The selectivity of VCN oncolytic adenoviruses allows their systemic administration, which is especially relevant for the treatment of disseminated cancer. Contrary to chemotherapy, the ability of oncolytic virus to self-amplify in tumor cells results in an effective dose increase with time. These properties highlight VCN candidates as promising alternatives for the treatment of refractory tumors such as pancreatic adenocarcinomas, which is the current tumor target for its most advanced candidate, VCN-01.

vivebiotech

VIVEbiotech is a company fully specialized in lentiviral vectors with two areas of expertise: 1. GMP CDMO: GMP Contract Development and Manufacturing Organization specialized in lentiviral vector bioprocess development (from very early stages) and GMP manufacturing 2. Innovation: VIVEbiotech´ strategy is focused on providing a response to the main hurdles that currently exist within the gene therapy field: a. The need for cost-effective processes. b.The enhancement of the safety profile of viral vectors: worldwide licensed non-integrative episomal stable lentiviral vector (LENTISOMA). VIVEbiotech is currently working with Companies based both in Europe and USA being our main aim being flexible in terms of technical adaptation and slots availability.

Biomarin

With six products on the market and a fully-integrated multinational organization in place, BioMarin is providing innovative therapeutics to patients with serious unmet medical needs. The company is also currently conducting a clinical trial of an AAV-based potential gene therapy for hemophilia A.

Euroclone

In the early 80s’ the establishment of CELBIO represented a true milestone, as this Company quickly became a reference for a number of scientists, giving them a valuable opportunity to gain access to a world of products and equipment in Biotechnology. Later on, this name became familiar also in the Medical and Diagnostic field. This leading approach remained unchanged and possibly improved throughout almost three decades, reinforcing the image of this Company as a reliable and solid partner for the entire scientific community.

At the beginning of the 90s' a sister Company called Euroclone® started its activity with the goal of giving more emphasis to the development of smart ideas which were felt to evolve into nice products to sell. The success was such that in 2009 it was decided to merge the two Companies, and CELBIO was fully incorporated into Euroclone®.

As a matter of fact, Euroclone® nowadays is bringing into the market the “passion” of the early days (since has inherited the Distribution of a panel of well known brands) along with a clear and growing interest in innovative and state-of-the art technologies originated by in-house R&D as well as obtained under private label and OEM agreement with the most qualifi ed manufacturers worldwide.

In other words, Euroclone® continues the tradition of CELBIO, while evolving into a modern supplier of up-to-date and own-branded products, thus reconfirming its position as a key-provider for a number of laboratories and clinics.

Viralgen

Viralgen vector Core is a new Company focused on GMP Development and Manufacturing of AAV. We are able to produce Research, Preclinical and GMP-grade batches. Our objective is became the CDMO leading in the sector of gene therapy and innovative medicines in Europe and US for developing and manufacturing in order to contribute to the progress in the health and welfare of people.

 

Audentes

Audentes Therapeutics is a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases.  Audentes is currently developing four product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

Abeona

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB- 101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). Abeona is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV- FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing its proprietary vector platform, AIM™, for next generation product candidates.

Bronce

Genethon

Genethon, located in Evry, France, is a non-profit R&D organization dedicated to the design and development of gene therapy treatments for rare genetic diseases from research to clinical validation. It was created by the AFM-Telethon (French Muscular Dystrophy Association) which is its main funding source. Genethon has multiple ongoing programs at clinical, preclinical and research stage for neuromuscular, blood, immune system, and liver diseases. Several of these programs are pursued by Genethon as sponsor, others have been licensed to leading biotech and pharma players in the gene therapy arena such as Audentes, Avexis/Novartis, Gensight Biologics, Orchard Therapeutics, Spark. Genethon was awarded the “Prix Galien France” in 2012.

Eurofancolen

Fanconi anemia (FA) is a rare inherited syndrome characterized by the early development of bone marrow failure and increasing predisposition to cancer with age. Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for hematopoietic manifestations of FA, although associated with complications arising from myeloablation, graft versus host disease and increased incidence of squamous cell carcinoma. The genetic correction of autologous hematopoietic stem cells (HSC) with lentiviral vectors constitutes a recent and safe alternative for the treatment of different genetic diseases affecting mature cells from different tissues and/or committed progenitors of the hematopoietic system. One of the key features of FA that make it a unique disease for gene therapy approaches rely on the characteristic proliferation defect that is already evident in the very primitive HSCs. Thus, a marked survival advantage would be expected from corrected HSCs, potentially allowing normalization of hematopoiesis in the absence or after mild conditioning. Difficulties in the collection of sufficient numbers of HSC from FA patients and the use of sub-optimal transduction protocols with gammaretroviral vectors limited the success of FA gene therapy trials conducted 10 years ago in the USA. EuroFancoLen innovative approach is to develop for the first time an efficient and safe gene therapy of FA based on two recent innovations: 1) Discovery of potent HSC mobilizers, such as plerixafor Ans 2) Development of a new lentiviral vector by members of this Consortium, designed as Orphan Drug by the Europan Commission in December 2010: The main objective of this project is, therefore, the development of a multicentric Phase I/II gene therapy trial for FA-A patients, based on the genetic correction of plerixafor+G-CSF mobilized HSCs with the novel lentiviral vector, accompanied by comprehensive and groundbreaking safety and efficacy patient monitoring estudies.

Ciberer

Rare diseases, affecting around 3 million Spanish people, are a social and health problem of the first order. The Centre for Biomedical Network Research on Rare Diseases (CIBERER), a network structure set up at the initiative of the Instituto de Salud Carlos III, pools and furthers the excellence research done in this country with the aim of finding diagnoses and therapies for those affected as quickly as possible.

Plasmid Factory

PlasmidFactory GmbH & Co. KG is a globally active biopharmaceutical company, founded in Bielefeld, Germany, in 2000. As a leading contract manufacturing organization (CMO) for plasmid and minicircle DNA, it has a strong customer base in the fields of cancer research, gene and cell therapy, CAR-T-cell development, and vaccination. PlasmidFactory produces plasmids and minicircles according to customer's requirements in modern laboratories with high quality standards. In addition to its In Stock products, e.g. for the worldwide exclusively offered pDG/pDP AAV 2-plasmid-system, and custom manufacturing of plasmid and minicircle DNA, PlasmidFactory focuses its R&D efforts on its core competencies in the production, analysis, application, and storage of DNA.